S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer|
|Federman & Sherwood Investigates CytRx Corporation for Possible Violations of Federal Securities Laws|
|CytRx Launches Discovery Laboratory to Develop Albumin-Binding Anti-Cancer Drug Platform|
|CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting|
|CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer|
|CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress|
|CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Gemcitabine in Patients with Metastatic Solid Tumors|
|CytRx Announces Unexpected Passing of Chairman Max Link, PhD|
|CytRx Appoints Steven A. Kriegsman as Chairman of the Board|
|CytRx Announces Publication of Phase 1b/2 Aldoxorubicin Clinical Data in Soft Tissue Sarcoma in Cancer, the Peer-Reviewed Journal of the American Cancer Society|
Click above to view more mutual fund data and stats for cx5n - CytRx Corp.